Key facts
- It has raised $35.0M across 6 recorded rounds; the latest was Later Stage VC (Series B) ($35.0M) in May 2022.
- Locus Biosciences has filed 8 Form Ds with the SEC since 2016, most recently Feb 2022 ($10.6M sold to 3 investors).
Free account
See the evidence behind this price
- ·Post-money valuations for all 6 rounds
- ·Watchlist + deal alerts for Locus Biosciences
Create free account
No card required
Funding rounds
6 roundsMay 2022Later Stage VC (Series B)$35.0M▮
About Locus Biosciences
- Industry
- Biotechnology
PA Mark — not yet priced
Locus Biosciences doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Pro members can request priority coverage with a 48-hour turnaround.
Recorded secondary trades
No prints on record
No secondary trades in Locus Biosciences shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Pro members can request priority coverage with a 48-hour turnaround.
Institutional fund marks
No fund marks yet
No SEC-registered fund has reported a fair-value mark on Locus Biosciences in its N-PORT filings yet. We sweep new filings monthly.
Pro members can request priority coverage with a 48-hour turnaround.